ESC 365 - Practical dimensions and optimal deployment of oral factor Xa inhibitors in patients with non-valvular atrial fibrillation: the role of key clinical factors.

Open Access

Practical dimensions and optimal deployment of oral factor Xa inhibitors in patients with non-valvular atrial fibrillation: the role of key clinical factors.

Session: Practical dimensions of novel anticoagulant-based prevention of stroke in atrial fibrillation and management of acute venous thromboembolism

Topic: Atrial fibrillation (AF)

Speaker: Doctor J. Cox (Halifax, CA)

Sponsored by Bayer Pharma AG

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Doctor Jafna Cox

Dalhousie University, Halifax (Canada)

6 presentations

0 follower

4 more presentations in this session

Introduction and welcome: evidence and guideline-based validation for factor Xa-based management of thrombosis-related disorders in cardiovascular medicine.

Speaker: Doctor S. Goldhaber (Boston, US)

Interactive case-based simulation focused on stroke prevention in atrial fibrillation: practical, real world management decisions using oral factor Xa inhibitors in patients with non-valvular atrial fibrillation.

Speaker: Professor R. De Caterina (Pisa, IT)

Practical issues for use of oral factor Xa inhibition in patients with acute pulmonary embolism and deep vein thrombosis.

Speaker: Professor A. Kakkar (London, GB)

Summary and take home messages: the foundation role of oral factor Xa inhibition for stroke prevention in atrial fibrillation and acute and extended management of venous thromboembolism.

Speaker: Doctor S. Goldhaber (Boston, US)

Access the full session

Practical dimensions of novel anticoagulant-based prevention of stroke in atrial fibrillation and management of acute venous thromboembolism

Speakers: Doctor J. Cox, Doctor S. Goldhaber, Professor R. De Caterina, Professor A. Kakkar, Doctor S. Goldhaber

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources